18,282 Shares in Natera, Inc. (NASDAQ:NTRA) Bought by SeaBridge Investment Advisors LLC

SeaBridge Investment Advisors LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,282 shares of the medical research company's stock, valued at approximately $2,894,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of NTRA. Covestor Ltd lifted its position in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after buying an additional 95 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC increased its position in shares of Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock valued at $55,000 after buying an additional 106 shares in the last quarter. Hanseatic Management Services Inc. increased its position in shares of Natera by 12.0% in the 4th quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company's stock valued at $158,000 after buying an additional 107 shares in the last quarter. Finally, Salem Investment Counselors Inc. increased its holdings in Natera by 0.7% during the 4th quarter. Salem Investment Counselors Inc. now owns 16,280 shares of the medical research company's stock worth $2,577,000 after purchasing an additional 110 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Stock Up 1.6 %

Shares of NASDAQ:NTRA traded up $2.86 during trading on Wednesday, reaching $177.10. The stock had a trading volume of 568,505 shares, compared to its average volume of 1,360,295. Natera, Inc. has a one year low of $67.33 and a one year high of $183.00. The company has a market capitalization of $23.38 billion, a P/E ratio of -100.51 and a beta of 1.66. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm's 50-day simple moving average is $167.26 and its 200 day simple moving average is $139.52.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business's quarterly revenue was up 63.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.95) EPS. As a group, research analysts expect that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NTRA. Barclays started coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 target price for the company. StockNews.com lowered shares of Natera from a "hold" rating to a "sell" rating in a report on Thursday, November 14th. Robert W. Baird upped their price objective on shares of Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. boosted their target price on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. Finally, Sanford C. Bernstein upped their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $165.88.

Insiders Place Their Bets

In related news, CFO Michael Burkes Brophy sold 43,502 shares of Natera stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $176.88, for a total transaction of $7,694,633.76. Following the completion of the sale, the chief financial officer now owns 70,629 shares in the company, valued at approximately $12,492,857.52. This trade represents a 38.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 2,212 shares of the business's stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total value of $350,668.36. Following the transaction, the director now directly owns 19,386 shares in the company, valued at $3,073,262.58. This trade represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 311,731 shares of company stock worth $52,215,659 over the last three months. Company insiders own 7.60% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.